Moreno, VictorRoda, DesamparadosPikiel, JoannaTrigo, JoseBosch-Barrera, JoaquimDrew, YvetteKristeleit, RebeccaHiret, SandrineBajor, David LCruz, PatriciaBeck, J ThaddeusGhosh, SrimoyeeDabrowski, ChristineAntony, GraceDuan, TaoVeneris, JenniferZografos, EleftheriosSubramanian, Janakiraman2023-05-032023-05-032022-05-19Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, et al. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clin Lung Cancer. 2022 Nov;23(7):e415-e427http://hdl.handle.net/10668/22104Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort expansion) GARNET study (NCT02715284). Here, we report an interim analysis of patients with recurrent/advanced NSCLC who progressed following platinum-based chemotherapy. Patients received dostarlimab (500 mg IV every 3 weeks [Q3W] for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity for > 2 years. The primary endpoints were immune-related objective response rate (irORR) per investigator-assessed irRECIST and safety. As of 8, July 2019, 67 patients with recurrent/advanced NSCLC were enrolled and treated with dostarlimab; the majority had programmed death ligand 1 (PD-L1) tumor proportion score (TPS) Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Cancer immunityImmune checkpoint inhibitorsLung neoplasmsPD-1Treatment outcomeHumansAntibodies, monoclonal, humanizedB7-H1 AntigenCarcinoma, non-small-cell lungImmune checkpoint inhibitorsLung neoplasmsNeoplasm recurrence, localClinical trials, phase I as topicresearch article35729005open accessAnticuerpos monoclonales humanizadosAntígeno B7-H1Carcinoma de pulmón de células no pequeñasEnsayos Clínicos Fase I como AsuntoNeoplasias Pulmonares10.1016/j.cllc.2022.05.0131938-0690http://www.clinical-lung-cancer.com/article/S1525730422001152/pdf